Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection

Yueh Ming Loo, David M. Owen, Kui Li, Andrea K. Erickson, Cynthia L. Johnson, Penny M. Fish, D. Spencer Carney, Ting Wang, Hisashi Ishida, Mitsutoshi Yoneyama, Takashi Fujita, Takeshi Saito, William M. Lee, Curt H. Hagedorn, Daryl T.Y. Lau, Steven A. Weinman, Stanley M. Lemon, Michael Gale

Research output: Contribution to journalArticle

310 Citations (Scopus)

Abstract

Viral signaling through retinoic acid-inducible gene-I (RIG-I) and its adaptor protein, IFN promoter-stimulator 1 (IPS-1), activates IFN regulatory factor-3 (IRF-3) and the host IFN-α/β response that limits virus infection. The hepatitis C virus (HCV) NS3/4A protease cleaves IPS-1 to block RIG-I signaling, but how this regulation controls the host response to HCV is not known. Moreover, endogenous IPS-1 cleavage has not been demonstrated in the context of HCV infection in vitro or in vivo. Here, we show that HCV infection transiently induces RIG-I- and IPS-1-dependent IRF-3 activation. This host response limits HCV production and constrains cellular permissiveness to infection. However, HCV disrupts this response early in infection by NS3/4A cleavage of IPS-1 at C508, releasing IPS-1 from the mitochondrial membrane. Cleavage results in subcellular redistribution of IPS-1 and loss of interaction with RIG-I, thereby preventing downstream activation of IRF-3 and IFN-β induction. Liver tissues from chronically infected patients similarly demonstrate subcellular redistribution of IPS-1 in infected hepatocytes and IPS-1 cleavage associated with a lack of ISG15 expression and conjugation of target proteins in vivo. Importantly, small-molecule inhibitors of NS3/4A prevent cleavage and restore RIG-I signaling of IFN-β induction. Our results suggest a dynamic model in which early activation of IRF-3 and induction of antiviral genes are reversed by IPS-1 proteolysis and abrogation of RIG-I signaling as NS3/4A accumulates in newly infected cells. HCV protease inhibitors effectively prevent IPS-1 proteolysis, suggesting they may be capable of restoring this innate host response in clinical practice.

Original languageEnglish (US)
Pages (from-to)6001-6006
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number15
DOIs
StatePublished - Apr 11 2006
Externally publishedYes

Fingerprint

Virus Diseases
Hepacivirus
Tretinoin
Interferon Regulatory Factor-3
Genes
Therapeutics
Proteolysis
Permissiveness
Mitochondrial Membranes
Infection
Protease Inhibitors
Antiviral Agents
Hepatocytes
Proteins
Liver

All Science Journal Classification (ASJC) codes

  • General

Cite this

Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. / Loo, Yueh Ming; Owen, David M.; Li, Kui; Erickson, Andrea K.; Johnson, Cynthia L.; Fish, Penny M.; Carney, D. Spencer; Wang, Ting; Ishida, Hisashi; Yoneyama, Mitsutoshi; Fujita, Takashi; Saito, Takeshi; Lee, William M.; Hagedorn, Curt H.; Lau, Daryl T.Y.; Weinman, Steven A.; Lemon, Stanley M.; Gale, Michael.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 15, 11.04.2006, p. 6001-6006.

Research output: Contribution to journalArticle

Loo, YM, Owen, DM, Li, K, Erickson, AK, Johnson, CL, Fish, PM, Carney, DS, Wang, T, Ishida, H, Yoneyama, M, Fujita, T, Saito, T, Lee, WM, Hagedorn, CH, Lau, DTY, Weinman, SA, Lemon, SM & Gale, M 2006, 'Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection', Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 15, pp. 6001-6006. https://doi.org/10.1073/pnas.0601523103
Loo, Yueh Ming ; Owen, David M. ; Li, Kui ; Erickson, Andrea K. ; Johnson, Cynthia L. ; Fish, Penny M. ; Carney, D. Spencer ; Wang, Ting ; Ishida, Hisashi ; Yoneyama, Mitsutoshi ; Fujita, Takashi ; Saito, Takeshi ; Lee, William M. ; Hagedorn, Curt H. ; Lau, Daryl T.Y. ; Weinman, Steven A. ; Lemon, Stanley M. ; Gale, Michael. / Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 15. pp. 6001-6006.
@article{166e71e98ecb48a4a83bcba875626929,
title = "Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection",
abstract = "Viral signaling through retinoic acid-inducible gene-I (RIG-I) and its adaptor protein, IFN promoter-stimulator 1 (IPS-1), activates IFN regulatory factor-3 (IRF-3) and the host IFN-α/β response that limits virus infection. The hepatitis C virus (HCV) NS3/4A protease cleaves IPS-1 to block RIG-I signaling, but how this regulation controls the host response to HCV is not known. Moreover, endogenous IPS-1 cleavage has not been demonstrated in the context of HCV infection in vitro or in vivo. Here, we show that HCV infection transiently induces RIG-I- and IPS-1-dependent IRF-3 activation. This host response limits HCV production and constrains cellular permissiveness to infection. However, HCV disrupts this response early in infection by NS3/4A cleavage of IPS-1 at C508, releasing IPS-1 from the mitochondrial membrane. Cleavage results in subcellular redistribution of IPS-1 and loss of interaction with RIG-I, thereby preventing downstream activation of IRF-3 and IFN-β induction. Liver tissues from chronically infected patients similarly demonstrate subcellular redistribution of IPS-1 in infected hepatocytes and IPS-1 cleavage associated with a lack of ISG15 expression and conjugation of target proteins in vivo. Importantly, small-molecule inhibitors of NS3/4A prevent cleavage and restore RIG-I signaling of IFN-β induction. Our results suggest a dynamic model in which early activation of IRF-3 and induction of antiviral genes are reversed by IPS-1 proteolysis and abrogation of RIG-I signaling as NS3/4A accumulates in newly infected cells. HCV protease inhibitors effectively prevent IPS-1 proteolysis, suggesting they may be capable of restoring this innate host response in clinical practice.",
author = "Loo, {Yueh Ming} and Owen, {David M.} and Kui Li and Erickson, {Andrea K.} and Johnson, {Cynthia L.} and Fish, {Penny M.} and Carney, {D. Spencer} and Ting Wang and Hisashi Ishida and Mitsutoshi Yoneyama and Takashi Fujita and Takeshi Saito and Lee, {William M.} and Hagedorn, {Curt H.} and Lau, {Daryl T.Y.} and Weinman, {Steven A.} and Lemon, {Stanley M.} and Michael Gale",
year = "2006",
month = "4",
day = "11",
doi = "10.1073/pnas.0601523103",
language = "English (US)",
volume = "103",
pages = "6001--6006",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "15",

}

TY - JOUR

T1 - Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection

AU - Loo, Yueh Ming

AU - Owen, David M.

AU - Li, Kui

AU - Erickson, Andrea K.

AU - Johnson, Cynthia L.

AU - Fish, Penny M.

AU - Carney, D. Spencer

AU - Wang, Ting

AU - Ishida, Hisashi

AU - Yoneyama, Mitsutoshi

AU - Fujita, Takashi

AU - Saito, Takeshi

AU - Lee, William M.

AU - Hagedorn, Curt H.

AU - Lau, Daryl T.Y.

AU - Weinman, Steven A.

AU - Lemon, Stanley M.

AU - Gale, Michael

PY - 2006/4/11

Y1 - 2006/4/11

N2 - Viral signaling through retinoic acid-inducible gene-I (RIG-I) and its adaptor protein, IFN promoter-stimulator 1 (IPS-1), activates IFN regulatory factor-3 (IRF-3) and the host IFN-α/β response that limits virus infection. The hepatitis C virus (HCV) NS3/4A protease cleaves IPS-1 to block RIG-I signaling, but how this regulation controls the host response to HCV is not known. Moreover, endogenous IPS-1 cleavage has not been demonstrated in the context of HCV infection in vitro or in vivo. Here, we show that HCV infection transiently induces RIG-I- and IPS-1-dependent IRF-3 activation. This host response limits HCV production and constrains cellular permissiveness to infection. However, HCV disrupts this response early in infection by NS3/4A cleavage of IPS-1 at C508, releasing IPS-1 from the mitochondrial membrane. Cleavage results in subcellular redistribution of IPS-1 and loss of interaction with RIG-I, thereby preventing downstream activation of IRF-3 and IFN-β induction. Liver tissues from chronically infected patients similarly demonstrate subcellular redistribution of IPS-1 in infected hepatocytes and IPS-1 cleavage associated with a lack of ISG15 expression and conjugation of target proteins in vivo. Importantly, small-molecule inhibitors of NS3/4A prevent cleavage and restore RIG-I signaling of IFN-β induction. Our results suggest a dynamic model in which early activation of IRF-3 and induction of antiviral genes are reversed by IPS-1 proteolysis and abrogation of RIG-I signaling as NS3/4A accumulates in newly infected cells. HCV protease inhibitors effectively prevent IPS-1 proteolysis, suggesting they may be capable of restoring this innate host response in clinical practice.

AB - Viral signaling through retinoic acid-inducible gene-I (RIG-I) and its adaptor protein, IFN promoter-stimulator 1 (IPS-1), activates IFN regulatory factor-3 (IRF-3) and the host IFN-α/β response that limits virus infection. The hepatitis C virus (HCV) NS3/4A protease cleaves IPS-1 to block RIG-I signaling, but how this regulation controls the host response to HCV is not known. Moreover, endogenous IPS-1 cleavage has not been demonstrated in the context of HCV infection in vitro or in vivo. Here, we show that HCV infection transiently induces RIG-I- and IPS-1-dependent IRF-3 activation. This host response limits HCV production and constrains cellular permissiveness to infection. However, HCV disrupts this response early in infection by NS3/4A cleavage of IPS-1 at C508, releasing IPS-1 from the mitochondrial membrane. Cleavage results in subcellular redistribution of IPS-1 and loss of interaction with RIG-I, thereby preventing downstream activation of IRF-3 and IFN-β induction. Liver tissues from chronically infected patients similarly demonstrate subcellular redistribution of IPS-1 in infected hepatocytes and IPS-1 cleavage associated with a lack of ISG15 expression and conjugation of target proteins in vivo. Importantly, small-molecule inhibitors of NS3/4A prevent cleavage and restore RIG-I signaling of IFN-β induction. Our results suggest a dynamic model in which early activation of IRF-3 and induction of antiviral genes are reversed by IPS-1 proteolysis and abrogation of RIG-I signaling as NS3/4A accumulates in newly infected cells. HCV protease inhibitors effectively prevent IPS-1 proteolysis, suggesting they may be capable of restoring this innate host response in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=33645805870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645805870&partnerID=8YFLogxK

U2 - 10.1073/pnas.0601523103

DO - 10.1073/pnas.0601523103

M3 - Article

VL - 103

SP - 6001

EP - 6006

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 15

ER -